Abstract

Info

Title:: Doxorubicin-eluting beads vs conventional TACE for hepatocellular carcinoma: a Meta-analysis

Author(s):: ZHOU Zhaiwen1; WANG Ziyu2; 3; CHEN Qinlian2; 3; HUANG Junhai3; 1. Department of Radiology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China; 2. the First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou 510405, China; 3. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China

Keywords:: ; Keywords: hepatocellular carcinoma; drug-eluting bead transarterial chemoembolization; Meta-analysis; therapeutic efficacy

Abstract:: Abstract: Objective To conduct a Meta-analysis for assessing the therapeutic efficacy and safety of doxorubicin-eluting bead transcatheter arterial chemoembolization (DEB-TACE) vs conventional TACE (C-TACE) in the treatment of hepatocellular carcinoma (HCC). Methods The relevant studies on DEB-TACE and C-TACE for HCC were searched from PubMed, Web of Science and CKIN databases. The tumor responds and adverse events in the selected studies were analyzed with RevMan5.0 statistical software. Moreover, publication bias was assessed by a funnel plot. Results Thirteen studies with 1 325 HCC patients were finally included in this analysis. The tumor response to DEB-TACE was better than that to C-TACE (OR: 2.28; 95%CI ［1.75, 2.96］; P<0.001 0). The risk of adverse events in DEB-TACE group was also lower than that in C-TACE group (RR: 0.56; 95%CI ［0.32, 0.97］; P=0.04). Conclusion Compared with C-TACE, DEB-TACE is more effective and has lower risk of adverse events in the treatment of HCC.